<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68051">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219945</url>
  </required_header>
  <id_info>
    <org_study_id>TBDIAGNOSE</org_study_id>
    <secondary_id>KE/FK/859/EC</secondary_id>
    <nct_id>NCT02219945</nct_id>
  </id_info>
  <brief_title>ENOSE in Pulmonary Tuberculosis in Yogyakarta</brief_title>
  <acronym>YOGYATBNOSE</acronym>
  <official_title>The Accuracy of the eNose in the Diagnostics and Monitoring of Treatment of Treatment-naive TB Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tjip van der Werf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gadjah Mada University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Enose Company, Zutphen the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic noses detecting patterns of volatile molecules have recently been introduced for
      different diagnostic purposes. The diagnostic accuracy of a prototype e-nose device (Bruins
      et al (2013) in Bangladesh showed sensitivity of 76.5-95.9% and specificity of 85.3-98.5%.
      Here the investigators test a production type point-of-care hand-held device with less
      detectors. The investigators explore factors such as food intake, smoking, and co-morbidity,
      as well as the impact of TB treatment, and address the question whether the device could
      help monitor disease and response to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants provide WIC and after time for consideration, when they approve, provide
      demographic anonymized data.

      The study population consists of six groups:

      Group 1 - 20 TB patients aged &gt; 18 yrs Group 2 - 20 non--‚ÄêTB patients &gt; 18 yrs (screened for
      TB - other conditions) Group 3 - 20 patients with a lung disease - no TB suspects (Lung
      Clinics in Yogyakarta,Indonesia; Group 4 - 50 apparently healthy matched controls Group 5 -
      20 newly diagnosed TB patients enrolled before start of treatment, to be followed over time,
      until after end of treatment (8 months FU).

      Group 6 - 50 apparently healthy volunteers.

      Study participants breath normally by mouthpiece into the device using a nose clamp - for 5
      min during each sampling.

      Electronic data are downloaded and transmitted by internet to Zutphen, Netherlands where
      data are processed to build the model.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic precision of electronic nose signal in pulmonary TB</measure>
    <time_frame>18 months</time_frame>
    <description>sensitivity and specificity of electronic nose signal in diagnosing and measuring response to treatment in pulmonary TB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measuring response to TB treatment over time with the electronic nose</measure>
    <time_frame>18 months</time_frame>
    <description>cohort of patients newly deteted with PTB will be followed with the enose device over time to monitor disease activity, until end of treatment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Pulmonary Tuberculosis Suspected</condition>
  <condition>Other Specified Chronic Obstructive Pulmonary Disease</condition>
  <condition>Pulmonary Tuberculosis TB (+) Histology, (-) Bacteriology</condition>
  <arm_group>
    <arm_group_label>Group 1 - 20 PTB patients aged &gt;18yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - 20 TB patients aged &gt; 18 yrs 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 20 TB suspects &gt; 18 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - 20 non-TB patients &gt; 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 - 20 lung patients, non-TB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - 50 healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 - 50 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 - 20 newly diagnosed PTB pts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 - 20 newly diagnosed TB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 6 - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 more healthy controls, not necessarily matched for gender and age, will be invited to participate to build the model to assess the test characterictics of the enose 5 min exhaled breath sampling with nose clamp</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>5 min exhaled breath sampling with soft nose clamp</intervention_name>
    <description>study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc</description>
    <arm_group_label>Group 1 - 20 PTB patients aged &gt;18yrs</arm_group_label>
    <arm_group_label>Group 2 - 20 TB suspects &gt; 18 yrs</arm_group_label>
    <arm_group_label>group 3 - 20 lung patients, non-TB</arm_group_label>
    <arm_group_label>Group 4 - 50 healthy controls</arm_group_label>
    <arm_group_label>Group 5 - 20 newly diagnosed PTB pts</arm_group_label>
    <arm_group_label>group 6 - healthy volunteers</arm_group_label>
    <other_name>AEONOSE portable exhaled breath sampling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18yrs

          -  voluntarily participating

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tjip S van der Werf, MD PhD</last_name>
    <phone>0031503611501</phone>
    <email>t.s.van.der.werf@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ymkje Stienstra, MD PhD MSc</last_name>
    <phone>0031503614764</phone>
    <email>y.stienstra@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>patients - at 5 lung clinics (Minggiran, Kalasan, Kotagede, Bantul, Kuonprogo) connected with Sudjarto Teachnig Hospital; healthy controls among students and staff of Hospital and Gadjah Mada Universitas</name>
      <address>
        <city>Yogyakarta</city>
        <state>Jalan Kesehatan no.1, Yogyakarta</state>
        <zip>55281</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Morita I Saktiawati, MD</last_name>
      <phone>011 62274553119</phone>
      <email>a.morita@ugm.ac.id</email>
    </contact>
    <contact_backup>
      <last_name>Yanri W Subronto, PhD</last_name>
      <phone>011 0811255030</phone>
      <email>ysubronto@jahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 15, 2014</lastchanged_date>
  <firstreceived_date>August 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>Tjip van der Werf</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pulmonary tuberculosis; electronic nose; diagnostic accuracy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
